Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer

NATICK, Mass. and QUINCY, Mass., April 26, 2023. Avenge Bio, Inc. ( " Avenge " ), a clinical stage, oncology-focused biotechnology company developing the LOCOcyte Immunotherapy platform for the precision administration of potent immune effector...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials